Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.61 |
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | BLM | P54132 | 3/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179782 | 1.00 | GRM4 (0.61) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL179781 | 1.00 | GRM4 (0.61) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL7707996 | 0.87 | GGT1 (0.50) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5065224 | 0.83 | GGT1 (0.47) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5065228 | 0.81 | GGT1 (0.48) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5065225 | 0.79 | GGT1 (0.43) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL8687592 | 0.78 | GGT1 (0.65) | GGT1ARG1ARG2ALDH1A1BLM | |
| SCHEMBL9507610 | 0.78 | GGT1 (0.46) | GRM4GGT1ARG1ARG2ALDH1A1 | |
| SCHEMBL5063485 | 0.77 | GRM4 (1.00) | GRM4ALDH1A1FDPSBLMTYMS | |
| SCHEMBL12434713 | 0.76 | GGT1 (0.52) | GRM4GGT1ARG1ARG2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | GRM4 104/4885GGT1 199/4885ARG1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.